Replies to post #53491 on Biotech Values

[DewDiligence]

>I say "man-boobs" 'cause I can't spell gynecomastica or whatever right now.<

You came close—just drop the last “c” and you have it: gynecomastia.

Finasteride cuts circulating DHT by about 70%, which leaves enough DHT to prevent troublesome side effects in most patients while still being effective in preventing prostate cancer. Not such a bad tradeoff.

[DewDiligence]

Addendum on man-boobs: there’s an altogether different way to get them (assuming you want them): implants. #msg-22377709 is a case in point.

Seriously, I’m fairly sure that’s a man.

[AlpineBV_Miller]

Some of the most prominent oncology docs in the country are quietly running Phase II trials of pulsing hormone therapy in men with HSPC. Shortly after the pulse ends, they are giving the men T (shot or gel, depending on the center) to return their T levels to normal during the pause portion of the protocol.

Unless you've obsessively follow the PCa field, it's hard to describe how far the field has come in recognizing the serious side effects of constant hormone ablation. What was once merely a whisper 3-4 years ago is attracting a great deal of research interest and attention now.

Given this and the clinical data showing no relationship between T restoration and PCA, I'm not sure there is much cause for concern here.